TEL AVIV, Israel, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and Eric Hughes ...

KANSAS CITY, Mo. — Following Friday’s men’s basketball contest against Utah State, Payton Sandfort indicated that Iowa wouldn’t truly know what it’s made of until presented with a ...

Iowa got a harsh reality check on Friday. If the Hawkeyes are serious about their ambitions this season, they can’t afford to make a habit of flops like this. “It’s fun being undefeated ...

Studios like Warner Bros. or Paramount are part of large conglomerates, but the financial hit from a flop like “Furiosa: A Mad Max Saga” or “Babylon” is felt in a way it would not be at ...

Iowa got a harsh reality check on Friday. If the Hawkeyes are serious about their ambitions this season, they can’t afford to make a habit of flops like this. “It’s fun being undefeated but you don’t ...

"Flip smartphones are popular for their blend of style, functionality, and nostalgia. Their compact, foldable design saves space, making them convenient for pocket storage. When opened, they offer ...

Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today. From reproductive rights to climate change to Big Tech, The ...

Memphis Grizzlies wing Vince Williams Jr. hobbled off the floor late in the second quarter against the Denver Nuggets and had to be taken out of Tuesday's game at FedExForum. He's listed as ...

Ruben Amorim insists he has a plan to revive the career of Manchester United flop Mason Mount. The England international’s career has stalled alarmingly since his big money move to Old Trafford ...

The 'Reef Adapt' ... Researchers Use the Sounds of Healthy Coral Reefs to Encourage Growth of a New Species of Coral Larvae Oct. 23, 2024 — Healthy coral reefs echo with a chorus of grunts and ...

In its second pipeline-boosting deal in two days, Sanofi has pledged €469 million (around $490 million) upfront for rights to an anti-TL1A therapy being developed by Teva for inflammatory bowel ...